中国医学创新2024，Vol.21Issue(17)：128-131,4.DOI:10.3969/j.issn.1674-4985.2024.17.029
齐拉西酮联合碳酸锂治疗双相情感障碍躁狂发作的效果及对血清肌酸激酶、肌酸激酶同工酶的影响
Effect of Ziprasidone Combined with Lithium Carbonate on Manic Episode of Bipolar Disorder and Its Influence on Serum Creatine Kinase and Creatine Kinase Isoenzyme
曾巾芬 1邹蓉 1刘小军 1肖峰1
作者信息
- 1. 赣州市第三人民医院精神心理科 江西 赣州 341000
- 折叠
摘要
Abstract
Objective:To explore the effect of Ziprasidone+Lithium Carbonate on patients with bipolar disorder(BD)manic episode and its influence on serum creatine kinase and creatine kinase isoenzyme levels.Method:A total of 126 patients with BD manic episode admitted to the Third People's Hospital of Ganzhou from January to December 2021 were randomly divided into observation group and control group,with 63 cases in each group.The control group received Lithium Carbonate treatment,and the observation group received Ziprasidone+Lithium Carbonate treatment.The clinical efficacy and incidence of adverse reactions,Young mania rating scale(YMRS),positive and negative syndrome scale(PANSS),the levels of serum creatine kinase and creatine kinase isoenzyme before and after treatment were observed and compared between the two groups.Result:Compared with the control group,the total effective rate of the observation group was significantly higher(P<0.05).There was no significant difference in the incidence of adverse reactions between the two groups(P>0.05).After treatment,the scores of YMRS,PANSS,the levels of serum creatine kinase and creatine kinase isoenzymes in observation group were significantly lower than those in control group(P<0.05).Conclusion:Ziprasidone+Lithium Carbonate has a good effect in the treatment of patients with BD manic episode,which can effectively improve clinical symptoms,down-regulate serum creatine kinase and creatine kinase isoenzyme levels,and has a high safety.关键词
齐拉西酮/碳酸锂/双相情感障碍/躁狂发作Key words
Ziprasidone/Lithium Carbonate/Bipolar disorder/Manic episode引用本文复制引用
曾巾芬,邹蓉,刘小军,肖峰..齐拉西酮联合碳酸锂治疗双相情感障碍躁狂发作的效果及对血清肌酸激酶、肌酸激酶同工酶的影响[J].中国医学创新,2024,21(17):128-131,4.
